Zevra Therapeutics price target raised to $21 from $19 at Roth MKM

Roth MKM analyst Jonathan Aschoff raised the firm’s price target on Zevra Therapeutics to $21 from $19 and keeps a Buy rating on the shares. The firm cites the FDA having announced the approval of Miplyffa, or arimoclomol, in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C, stating that the company needs about 8-12 weeks to make the drug commercially available. While Roth MKM projects commercial sales starting in late Q4, the firm also expects that pent-up demand will lead to a robust bolus of sales out of the gate, the analyst tells investors in a research note, adding that the likely sale of its priority review voucher would go a long way toward funding product launches and potentially acquiring new products.